Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease

Levodopa-induced dyskinesia (LID) is a common motor complication in patients with Parkinson’s disease on chronic levodopa therapy. The management of LID is important as dyskinesia can be disabling and impair quality of life. Currently, there are limited treatment options for the medical management o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Vibhash D, Lyons, Kelly E, Pahwa, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905495/
https://www.ncbi.nlm.nih.gov/pubmed/29695911
http://dx.doi.org/10.2147/TCRM.S144481
_version_ 1783315274237214720
author Sharma, Vibhash D
Lyons, Kelly E
Pahwa, Rajesh
author_facet Sharma, Vibhash D
Lyons, Kelly E
Pahwa, Rajesh
author_sort Sharma, Vibhash D
collection PubMed
description Levodopa-induced dyskinesia (LID) is a common motor complication in patients with Parkinson’s disease on chronic levodopa therapy. The management of LID is important as dyskinesia can be disabling and impair quality of life. Currently, there are limited treatment options for the medical management of LID. Amantadine extended-release capsules (Gocovri™) is the first medication that received US Food and Drug Administration approval for the treatment of LID. The following is a review of the pharmacodynamics, efficacy and safety profile, and current state of treatment of amantadine for LID.
format Online
Article
Text
id pubmed-5905495
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59054952018-04-25 Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease Sharma, Vibhash D Lyons, Kelly E Pahwa, Rajesh Ther Clin Risk Manag Review Levodopa-induced dyskinesia (LID) is a common motor complication in patients with Parkinson’s disease on chronic levodopa therapy. The management of LID is important as dyskinesia can be disabling and impair quality of life. Currently, there are limited treatment options for the medical management of LID. Amantadine extended-release capsules (Gocovri™) is the first medication that received US Food and Drug Administration approval for the treatment of LID. The following is a review of the pharmacodynamics, efficacy and safety profile, and current state of treatment of amantadine for LID. Dove Medical Press 2018-04-12 /pmc/articles/PMC5905495/ /pubmed/29695911 http://dx.doi.org/10.2147/TCRM.S144481 Text en © 2018 Sharma et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Sharma, Vibhash D
Lyons, Kelly E
Pahwa, Rajesh
Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
title Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
title_full Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
title_fullStr Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
title_full_unstemmed Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
title_short Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
title_sort amantadine extended-release capsules for levodopa-induced dyskinesia in patients with parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905495/
https://www.ncbi.nlm.nih.gov/pubmed/29695911
http://dx.doi.org/10.2147/TCRM.S144481
work_keys_str_mv AT sharmavibhashd amantadineextendedreleasecapsulesforlevodopainduceddyskinesiainpatientswithparkinsonsdisease
AT lyonskellye amantadineextendedreleasecapsulesforlevodopainduceddyskinesiainpatientswithparkinsonsdisease
AT pahwarajesh amantadineextendedreleasecapsulesforlevodopainduceddyskinesiainpatientswithparkinsonsdisease

Ejemplares similares